Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
17 12 2020
17 12 2020
Historique:
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
In response to the spread of SARS-CoV-2 and the impact of COVID-19, national and subnational governments implemented a variety of measures in order to control the spread of the virus and the associated disease. While these measures were imposed with the intention of controlling the pandemic, they were also associated with severe psychosocial, societal, and economic implications on a societal level. One setting affected heavily by these measures is the school setting. By mid-April 2020, 192 countries had closed schools, affecting more than 90% of the world's student population. In consideration of the adverse consequences of school closures, many countries around the world reopened their schools in the months after the initial closures. To safely reopen schools and keep them open, governments implemented a broad range of measures. The evidence with regards to these measures, however, is heterogeneous, with a multitude of study designs, populations, settings, interventions and outcomes being assessed. To make sense of this heterogeneity, we conducted a rapid scoping review (8 October to 5 November 2020). This rapid scoping review is intended to serve as a precursor to a systematic review of effectiveness, which will inform guidelines issued by the World Health Organization (WHO). This review is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and was registered with the Open Science Framework. To identify and comprehensively map the evidence assessing the impacts of measures implemented in the school setting to reopen schools, or keep schools open, or both, during the SARS-CoV-2/COVID-19 pandemic, with particular focus on the types of measures implemented in different school settings, the outcomes used to measure their impacts and the study types used to assess these. We searched the Cochrane COVID-19 Study Register, MEDLINE, Embase, the CDC COVID-19 Research Articles Downloadable Database for preprints, and the WHO COVID-19 Global literature on coronavirus disease on 8 October 2020. We included studies that assessed the impact of measures implemented in the school setting. Eligible populations were populations at risk of becoming infected with SARS-CoV-2, or developing COVID-19 disease, or both, and included people both directly and indirectly impacted by interventions, including students, teachers, other school staff, and contacts of these groups, as well as the broader community. We considered all types of empirical studies, which quantitatively assessed impact including epidemiological studies, modelling studies, mixed-methods studies, and diagnostic studies that assessed the impact of relevant interventions beyond diagnostic test accuracy. Broad outcome categories of interest included infectious disease transmission-related outcomes, other harmful or beneficial health-related outcomes, and societal, economic, and ecological implications. We extracted data from included studies in a standardized manner, and mapped them to categories within our a priori logic model where possible. Where not possible, we inductively developed new categories. In line with standard expectations for scoping reviews, the review provides an overview of the existing evidence regardless of methodological quality or risk of bias, and was not designed to synthesize effectiveness data, assess risk of bias, or characterize strength of evidence (GRADE). We included 42 studies that assessed measures implemented in the school setting. The majority of studies used mathematical modelling designs (n = 31), while nine studies used observational designs, and two studies used experimental or quasi-experimental designs. Studies conducted in real-world contexts or using real data focused on the WHO European region (EUR; n = 20), the WHO region of the Americas (AMR; n = 13), the West Pacific region (WPR; n = 6), and the WHO Eastern Mediterranean Region (EMR; n = 1). One study conducted a global assessment and one did not report on data from, or that were applicable to, a specific country. Three broad intervention categories emerged from the included studies: organizational measures to reduce transmission of SARS-CoV-2 (n = 36), structural/environmental measures to reduce transmission of SARS-CoV-2 (n = 11), and surveillance and response measures to detect SARS-CoV-2 infections (n = 19). Most studies assessed SARS-CoV-2 transmission-related outcomes (n = 29), while others assessed healthcare utilization (n = 8), other health outcomes (n = 3), and societal, economic, and ecological outcomes (n = 5). Studies assessed both harmful and beneficial outcomes across all outcome categories. We identified a heterogeneous and complex evidence base of measures implemented in the school setting. This review is an important first step in understanding the available evidence and will inform the development of rapid reviews on this topic.
Sections du résumé
BACKGROUND
In response to the spread of SARS-CoV-2 and the impact of COVID-19, national and subnational governments implemented a variety of measures in order to control the spread of the virus and the associated disease. While these measures were imposed with the intention of controlling the pandemic, they were also associated with severe psychosocial, societal, and economic implications on a societal level. One setting affected heavily by these measures is the school setting. By mid-April 2020, 192 countries had closed schools, affecting more than 90% of the world's student population. In consideration of the adverse consequences of school closures, many countries around the world reopened their schools in the months after the initial closures. To safely reopen schools and keep them open, governments implemented a broad range of measures. The evidence with regards to these measures, however, is heterogeneous, with a multitude of study designs, populations, settings, interventions and outcomes being assessed. To make sense of this heterogeneity, we conducted a rapid scoping review (8 October to 5 November 2020). This rapid scoping review is intended to serve as a precursor to a systematic review of effectiveness, which will inform guidelines issued by the World Health Organization (WHO). This review is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and was registered with the Open Science Framework.
OBJECTIVES
To identify and comprehensively map the evidence assessing the impacts of measures implemented in the school setting to reopen schools, or keep schools open, or both, during the SARS-CoV-2/COVID-19 pandemic, with particular focus on the types of measures implemented in different school settings, the outcomes used to measure their impacts and the study types used to assess these.
SEARCH METHODS
We searched the Cochrane COVID-19 Study Register, MEDLINE, Embase, the CDC COVID-19 Research Articles Downloadable Database for preprints, and the WHO COVID-19 Global literature on coronavirus disease on 8 October 2020.
SELECTION CRITERIA
We included studies that assessed the impact of measures implemented in the school setting. Eligible populations were populations at risk of becoming infected with SARS-CoV-2, or developing COVID-19 disease, or both, and included people both directly and indirectly impacted by interventions, including students, teachers, other school staff, and contacts of these groups, as well as the broader community. We considered all types of empirical studies, which quantitatively assessed impact including epidemiological studies, modelling studies, mixed-methods studies, and diagnostic studies that assessed the impact of relevant interventions beyond diagnostic test accuracy. Broad outcome categories of interest included infectious disease transmission-related outcomes, other harmful or beneficial health-related outcomes, and societal, economic, and ecological implications.
DATA COLLECTION AND ANALYSIS
We extracted data from included studies in a standardized manner, and mapped them to categories within our a priori logic model where possible. Where not possible, we inductively developed new categories. In line with standard expectations for scoping reviews, the review provides an overview of the existing evidence regardless of methodological quality or risk of bias, and was not designed to synthesize effectiveness data, assess risk of bias, or characterize strength of evidence (GRADE).
MAIN RESULTS
We included 42 studies that assessed measures implemented in the school setting. The majority of studies used mathematical modelling designs (n = 31), while nine studies used observational designs, and two studies used experimental or quasi-experimental designs. Studies conducted in real-world contexts or using real data focused on the WHO European region (EUR; n = 20), the WHO region of the Americas (AMR; n = 13), the West Pacific region (WPR; n = 6), and the WHO Eastern Mediterranean Region (EMR; n = 1). One study conducted a global assessment and one did not report on data from, or that were applicable to, a specific country. Three broad intervention categories emerged from the included studies: organizational measures to reduce transmission of SARS-CoV-2 (n = 36), structural/environmental measures to reduce transmission of SARS-CoV-2 (n = 11), and surveillance and response measures to detect SARS-CoV-2 infections (n = 19). Most studies assessed SARS-CoV-2 transmission-related outcomes (n = 29), while others assessed healthcare utilization (n = 8), other health outcomes (n = 3), and societal, economic, and ecological outcomes (n = 5). Studies assessed both harmful and beneficial outcomes across all outcome categories.
AUTHORS' CONCLUSIONS
We identified a heterogeneous and complex evidence base of measures implemented in the school setting. This review is an important first step in understanding the available evidence and will inform the development of rapid reviews on this topic.
Identifiants
pubmed: 33331665
doi: 10.1002/14651858.CD013812
pmc: PMC9206727
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD013812Subventions
Organisme : Medical Research Council
ID : MR/K023233/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Int J Infect Dis. 2020 Oct;99:57-61
pubmed: 32745628
BMC Med Res Methodol. 2018 Nov 19;18(1):143
pubmed: 30453902
J Public Health Manag Pract. 2008 Mar-Apr;14(2):117-23
pubmed: 18287916
Lancet Public Health. 2020 May;5(5):e261-e270
pubmed: 32220655
Euro Surveill. 2020 Sep;25(38):
pubmed: 32975186
Euro Surveill. 2020 Apr;25(13):
pubmed: 32265006
PLoS One. 2014 May 15;9(5):e97297
pubmed: 24830407
Syst Rev. 2022 May 12;11(1):90
pubmed: 35550674
Cochrane Database Syst Rev. 2020 Dec 17;12:CD013812
pubmed: 33331665
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Epidemics. 2021 Dec;37:100487
pubmed: 34425301
BMC Med. 2020 Jul 30;18(1):240
pubmed: 32727547
Epidemics. 2015 Dec;13:10-16
pubmed: 26097505
Front Pediatr. 2021 Jan 14;8:615894
pubmed: 33520898
Lancet Child Adolesc Health. 2020 Nov;4(11):817-827
pubmed: 32758453
BMC Infect Dis. 2021 May 30;21(1):503
pubmed: 34053446
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200261
pubmed: 34053259
Lancet Respir Med. 2020 May;8(5):433-434
pubmed: 32203709
Paediatr Respir Rev. 2015 Mar;16(2):119-26
pubmed: 24630149
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
Am J Occup Ther. 2013 Mar-Apr;67(2):146-53
pubmed: 23433268
BMJ Open. 2013 Feb 26;3(2):
pubmed: 23447463
Cochrane Database Syst Rev. 2020 Apr 8;4:CD013574
pubmed: 32267544
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Aug 10;41(8):1195-1196
pubmed: 32388935
Science. 2021 Mar 26;371(6536):
pubmed: 33531384
Infect Dis Model. 2020 Nov 13;6:24-35
pubmed: 33294745
GMS Hyg Infect Control. 2020 Sep 15;15:Doc22
pubmed: 32974120
J Glob Health. 2020 Dec;10(2):021104
pubmed: 33437465
Soc Sci Med. 2010 May;70(10):1467-74
pubmed: 20207059
F1000Res. 2020 May 12;9:352
pubmed: 32864104
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Apr 6;54(4):348-350
pubmed: 32268638
Nat Commun. 2021 Mar 29;12(1):1942
pubmed: 33782396
Physica D. 2021 Jan;415:132753
pubmed: 33024345
Euro Surveill. 2020 Sep;25(36):
pubmed: 32914746
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
JAMA Pediatr. 2020 Sep 1;174(9):819-820
pubmed: 32286618
PLoS One. 2021 May 20;16(5):e0251242
pubmed: 34014947
PLoS One. 2021 Apr 1;16(4):e0248828
pubmed: 33793570
Cad Saude Publica. 2020;36(8):e00150020
pubmed: 32876127
PLoS One. 2021 Feb 25;16(2):e0238268
pubmed: 33630842
Sci Rep. 2021 Mar 18;11(1):6402
pubmed: 33737555
Health Place. 2020 Jul;64:102398
pubmed: 32736311
Wellcome Open Res. 2020 May 1;5:83
pubmed: 32656368
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24575-24580
pubmed: 32887803
Emerg Infect Dis. 2021 Apr;27(4):1229-1231
pubmed: 33755002
Health Res Policy Syst. 2008 Jul 09;6:7
pubmed: 18613961
CMAJ. 2020 Sep 14;192(37):E1053-E1064
pubmed: 32778573
J Clin Epidemiol. 2017 Sep;89:21-29
pubmed: 28365303
J Korean Med Sci. 2020 Nov 30;35(46):e414
pubmed: 33258334
JAMA. 2020 Sep 1;324(9):833-834
pubmed: 32761241
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
Lancet Infect Dis. 2009 Aug;9(8):473-81
pubmed: 19628172
Saf Sci. 2021 Feb;134:105067
pubmed: 33162676
R Soc Open Sci. 2021 Jan 27;8(1):201566
pubmed: 33614088
BMC Pediatr. 2020 Sep 1;20(1):410
pubmed: 32873269
PeerJ. 2021 Mar 30;9:e11211
pubmed: 33850668
PLoS One. 2021 Mar 25;16(3):e0248509
pubmed: 33765026
Euro Surveill. 2020 Jul;25(29):
pubmed: 32720636
Lancet Infect Dis. 2020 Oct;20(10):1115-1117
pubmed: 32888409
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
J Infect Public Health. 2018 Sep - Oct;11(5):657-661
pubmed: 29396256
J Pediatr (Rio J). 2021 Jul-Aug;97(4):369-377
pubmed: 32980318
MMWR Morb Mortal Wkly Rep. 2020 Aug 07;69(31):1023-1025
pubmed: 32759921
BMC Public Health. 2022 Mar 14;22(1):496
pubmed: 35287631
Lancet Public Health. 2020 Jul;5(7):e375-e385
pubmed: 32502389
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
J Glob Health. 2020 Jun;10(1):011101
pubmed: 32612817
BMJ. 2020 Jul 15;370:m2743
pubmed: 32669358
Br J Dermatol. 2020 Nov;183(5):975-976
pubmed: 32697848
BMJ Paediatr Open. 2020 May 4;4(1):e000701
pubmed: 32420459
Sci Adv. 2021 May 7;7(19):
pubmed: 33962957
Arch Pediatr. 2020 Oct;27(7):388-392
pubmed: 32921531
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200277
pubmed: 34053270
Sci Rep. 2021 Apr 22;11(1):8747
pubmed: 33888818
JAMA Pediatr. 2020 Oct 1;174(10):928
pubmed: 32401279
BMC Med Res Methodol. 2016 Feb 09;16:15
pubmed: 26857112
Glob Epidemiol. 2020 Nov;2:100042
pubmed: 33235991
Dan Med J. 2020 Aug 6;67(9):
pubmed: 32800064
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Microbes Infect. 2020 Nov - Dec;22(10):611-616
pubmed: 32977019
BMJ Glob Health. 2020 Nov;5(11):
pubmed: 33234529
Arch Dis Child. 2021 Feb;106(2):111-113
pubmed: 32747375
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860747
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Implement Sci. 2017 Feb 15;12(1):21
pubmed: 28202031
J Korean Med Sci. 2020 Apr 06;35(13):e143
pubmed: 32242349
CMAJ. 2020 Oct 5;192(40):E1146-E1155
pubmed: 32907820
PLoS Comput Biol. 2021 Feb 11;17(2):e1008559
pubmed: 33571188
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
GMS Hyg Infect Control. 2020 May 28;15:Doc11
pubmed: 32547911
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Lancet. 2002 Jan 12;359(9301):145-9
pubmed: 11809274
JAMA Pediatr. 2020 Sep 01;174(9):882-889
pubmed: 32320004
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252